By Menopause Reviewed Editorial Team | Last reviewed: May 2026
Approximately one in two women over age 50 will break a bone because of osteoporosis — a figure from the Bone Health and Osteoporosis Foundation that most women have not heard from the physician handing them a calcium prescription. Hip fractures carry a 20 to 24 percent one-year mortality rate, and roughly half of survivors never return to independent living. These outcomes are the downstream consequence of a process that begins before most women have had their last menstrual period.
The Study of Women's Health Across the Nation (SWAN) Bone Substudy found that significant bone loss commences approximately one to two years before the final menstrual period (FMP), accelerates to roughly two percent per year at the lumbar spine through the first two to three years post-FMP, and then slows into a lower but persistent trajectory. Greendale et al., reporting SWAN data in the Journal of Bone and Mineral Research (2012), documented that total spinal bone mineral density (BMD) loss across the transition can reach six percent or more — a deterioration that unfolds over a few years and is not reversible through calcium tablets.
Understanding what actually interrupts this process requires moving past supplement marketing and into the biology.
The Biology: Why Estrogen Matters for Bone
Bone is not static tissue. It is continuously remodeled by two competing cell populations: osteoclasts, which resorb bone, and osteoblasts, which form it. Under normal conditions, these processes are held in rough equilibrium by the RANKL/OPG signaling axis. RANKL (receptor activator of nuclear factor kappa-B ligand) promotes osteoclast differentiation and activation. OPG (osteoprotegerin), produced by osteoblasts, acts as a decoy receptor that binds RANKL and blocks it from activating osteoclasts.
Estrogen is a key regulator of this equilibrium. It suppresses osteoclast activity through multiple pathways, including increasing OPG production and directly inducing osteoclast apoptosis. When estrogen levels fall during the menopause transition, the RANKL/OPG balance tips toward net resorption: osteoclasts become more active and more numerous while osteoblast function is comparatively insufficient to compensate. The result is a negative remodeling balance — more bone is removed with each cycle than is replaced.
This is why menopause-related bone loss is not simply a calcium deficiency problem. The underlying driver is hormonal, not nutritional.
Knowing Your Risk: FRAX, DEXA, and T-Scores
The FRAX tool, developed by the World Health Organization, integrates clinical risk factors — age, body weight, prior fracture, parental hip fracture, smoking, glucocorticoid use, rheumatoid arthritis, and alcohol consumption — to estimate 10-year probability of hip fracture and major osteoporotic fracture. It runs with or without BMD input and is freely available at sheffield.ac.uk/FRAX. It is the recommended first step in stratifying who needs pharmacologic intervention.
For formal bone density measurement, the US Preventive Services Task Force (USPSTF) issued a Grade B recommendation in 2025 to screen all women 65 years or older with DXA (dual-energy X-ray absorptiometry) — the diagnostic standard for measuring bone density. For postmenopausal women younger than 65 with one or more clinical risk factors (early menopause, low body weight, smoking, family history, prolonged glucocorticoid use), the USPSTF recommends risk-stratification with a formal tool followed by DXA if risk is elevated.
DXA results are expressed as a T-score: the number of standard deviations above or below the average BMD of a young healthy adult reference population. The WHO classifications are: normal (T-score at or above −1.0), osteopenia (−1.0 to −2.5), and osteoporosis (−2.5 or below). A single DXA test provides a snapshot; what SWAN research demonstrated is that the rate of loss matters as much as the starting value — women with below-median baseline BMD and above-median rates of decline had a 2.7-fold greater fracture hazard than women with both factors in the less severe range (Karlamangla, Shieh, et al., Journal of Clinical Endocrinology and Metabolism, 2021).
The Calcium Myth
The dominant message women receive about postmenopausal bone health is: take calcium. The research tells a more complicated story.
A 2015 meta-analysis by Bolland et al. in the BMJ, pooling randomized controlled trials examining calcium intake and fracture risk in adults over 50, found that increasing calcium intake from dietary sources is not associated with reduced fracture risk, and that evidence for fracture prevention from calcium supplements is "weak and inconsistent." The one population in which calcium supplementation showed significant fracture reduction was frail elderly institutionalized women with documented low dietary calcium and low vitamin D — a profile distinct from most community-dwelling postmenopausal women.
More concerning, the same research group's earlier 2010 meta-analysis in the BMJ found that calcium supplements (without vitamin D) were associated with approximately a 30 percent increase in risk of myocardial infarction across 11 randomized controlled trials involving around 12,000 participants. A subsequent 2011 analysis including trials of calcium with co-administered vitamin D found similar, if slightly attenuated, cardiovascular signals. The mechanism proposed involves acute elevations in serum calcium following bolus supplementation, which may promote arterial calcification and promote coagulation.
The practical implication is not that calcium intake is irrelevant to bone — it is a required substrate — but that the goal should be meeting calcium needs through dietary sources (dairy, leafy greens, fortified foods) rather than high-dose supplementation, and that the supplement most aggressively marketed to this population may carry meaningful cardiovascular risk without meaningful fracture benefit.
Vitamin D occupies a different position. In populations with documented deficiency (serum 25-hydroxyvitamin D below 20 ng/mL), correction to sufficient levels is associated with improved calcium absorption and reduced fracture risk. However, Bolland et al.'s 2018 systematic review in The Lancet Diabetes & Endocrinology, pooling 81 randomized controlled trials, found that vitamin D supplementation in people not selected for deficiency had no effect on total fracture, hip fracture, or falls. The takeaway: test first, supplement only when there is demonstrated deficiency.
What Actually Works
Resistance Training and Impact Loading
The most underutilized and well-validated intervention for postmenopausal bone is exercise — specifically, the kind most women are told to avoid.
The LIFTMOR (Lifting Intervention for Training Muscle and Osteoporosis Rehabilitation) randomized controlled trial, published in the Journal of Bone and Mineral Research in 2018 by Watson, Weeks, Weis, Beck, and colleagues, enrolled 101 postmenopausal women aged 65 on average with low bone mass (T-scores ranging into osteoporosis range). The intervention group performed supervised high-intensity resistance and impact training (HiRIT) — deadlifts, overhead presses, and drop jumps at loads exceeding 85 percent of one-repetition maximum — twice weekly for eight months. The control group performed a low-intensity home exercise program.
Results: the HiRIT group showed lumbar spine BMD gains of 2.9 percent versus a loss of 1.2 percent in controls (p < 0.001), and femoral neck BMD improved by 0.3 percent versus a loss of 1.9 percent in controls (p = 0.004). Only one adverse event (minor lower-back spasm causing two missed sessions) occurred in the HiRIT group across 8 months of heavy training. The finding that supervised high-intensity loading is both efficacious and safe in women with established low bone mass directly challenged the prevailing clinical advice that osteoporotic women should avoid high-impact exercise.
The mechanism is straightforward: skeletal tissue forms new bone only when mechanical strain exceeds a minimum threshold. Low-intensity walking applies strains well below that threshold at most skeletal sites; high-magnitude loading does not.
Menopausal Hormone Therapy
For women in the menopausal transition or early postmenopause who have both vasomotor symptoms and bone concerns, hormone therapy (HRT) addresses the proximate biological cause of bone loss.
The Women's Health Initiative hormone therapy trials provide the most direct evidence. Cauley and colleagues' analysis of the combined WHI cohort (25,389 women) found that MHT reduced the risk of any clinical fracture by 28 percent (HR 0.72), major osteoporotic fracture by 40 percent (HR 0.60), and hip fracture by 34 percent (HR 0.66) compared to placebo. A 2022 Osteoporosis International analysis by Lorentzon, Johansson, Harvey, Cauley et al. confirmed that these fracture reductions were consistent regardless of baseline FRAX probability and prior falls history — suggesting fracture protection does not depend on selecting only high-risk women.
Current guidance from the Menopause Society and the International Menopause Society positions HRT as first-line treatment for women younger than 60 or within 10 years of menopause who have both symptomatic and skeletal indications, in the absence of contraindications.
Pharmacological Agents
When bone loss is severe, symptomatic, or involves an insufficient response to lifestyle and HRT, several drug classes have robust fracture reduction data.
Bisphosphonates (alendronate, risedronate, zoledronic acid) are antiresorptive agents that bind to bone mineral and inhibit osteoclast activity. Annual intravenous zoledronic acid (HORIZON trial) reduced vertebral fracture risk by 70 percent and hip fracture risk by 41 percent versus placebo over three years.
Denosumab (Prolia) is a monoclonal antibody targeting RANKL. The FREEDOM trial (Cummings, San Martín, McClung et al., New England Journal of Medicine, 2009) demonstrated a 68 percent reduction in new vertebral fractures, 40 percent reduction in hip fractures, and 20 percent reduction in non-vertebral fractures over 36 months versus placebo. A critical caveat from FREEDOM extension analyses (Cummings et al., Journal of Bone and Mineral Research, 2018): stopping denosumab without transitioning to a bisphosphonate triggers rapid rebound bone loss and markedly elevated risk of multiple vertebral fractures within 12 to 24 months — a risk pattern not observed when stopping bisphosphonates.
Romosozumab (Evenity) inhibits sclerostin, simultaneously increasing bone formation and decreasing resorption. The ARCH trial (Saag et al., NEJM, 2017) found that 12 months of romosozumab followed by alendronate produced a 48 percent lower risk of new vertebral fracture at 24 months compared to alendronate alone. The ARCH trial also reported a numerically higher cardiovascular event rate in the romosozumab arm; the drug carries an FDA black box warning and is contraindicated within one year of myocardial infarction or stroke.
Teriparatide (Forteo), a parathyroid hormone receptor agonist, stimulates bone formation directly and is reserved for severe osteoporosis or antiresorptive failure, followed by an antiresorptive to consolidate gains.
A Note on BPC-157 and Bone Research
BPC-157, a synthetic pentadecapeptide derived from a gastric protein sequence, has generated interest in preclinical research for its effects on musculoskeletal tissue. A 2025 systematic review in the Journal of the American Academy of Orthopaedic Surgeons (Vasireddi et al.) found that across 36 identified studies from 1993 to 2024, 35 were preclinical animal studies; the one human study was a small retrospective case series for knee pain. Animal model data suggest BPC-157 may promote bone healing, tendon repair, and soft-tissue-to-bone junction healing through angiogenic and growth factor receptor pathways — but animal-to-human translation in musculoskeletal biology is historically unreliable, and no randomized controlled trials in humans currently exist.
BPC-157 is not FDA-approved for any bone-related indication, and its evidence base for bone health specifically remains preclinical and unvalidated in human trials.